Federal Judge Won’t Alter Dismissal Of GLP-1 Compounding Pharmacy’s Antitrust Case
SAN ANTONIO — A Texas federal judge left intact the dismissal with prejudice of a compounding pharmacy’s antitrust claims against the manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications approved...To view the full article, register now.
Already a subscriber? Click here to view full article